Penpulimab

Drug profile

Key facts

Penpulimab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2025. DrugCentral lists 1 molecular target, including PDCD1. Recorded indications include Metastatic non-keratinizing nasopharyngeal carcinoma.

• Molecular targets: PDCD1 (1 listed in DrugCentral).
• Indications: Metastatic non-keratinizing nasopharyngeal carcinoma.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Metastatic non-keratinizing nasopharyngeal carcinoma

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Programmed cell death protein 1	PDCD1	other	EC50 10.28

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2025-04-23	FDA	—	Akeso Biopharma Co., Ltd.	Yes

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Penpulimab used for?

DrugCentral lists the following indications for Penpulimab: Metastatic non-keratinizing nasopharyngeal carcinoma.

How does Penpulimab work?

Its molecular targets in DrugCentral include PDCD1.

When was Penpulimab first approved?

Penpulimab was first approved by the FDA in 2025.

Sources

• DrugCentral drug card 5768 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297571 — compound record and bioactivity
• DrugBank DB16747 — drug record
• FDA UNII IBS1BZ4E4I — substance identity
• DailyMed: FDA labels for Penpulimab — current prescribing information (label search)
• UniProt Q15116 (PDCD1) — target protein

How this page is built: methodology · editorial policy & corrections.